1. Home
  2. GSL vs VOR Comparison

GSL vs VOR Comparison

Compare GSL & VOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

GSL

Global Ship Lease Inc New

N/A

Current Price

$45.36

Market Cap

1.5B

ML Signal

N/A

Logo Vor Biopharma Inc.

VOR

Vor Biopharma Inc.

N/A

Current Price

$18.08

Market Cap

1.4B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
GSL
VOR
Founded
2007
2015
Country
Greece
United States
Employees
N/A
N/A
Industry
Marine Transportation
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.4B
IPO Year
2008
2021

Fundamental Metrics

Financial Performance
Metric
GSL
VOR
Price
$45.36
$18.08
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
9
Target Price
★ $51.00
$39.00
AVG Volume (30 Days)
246.0K
★ 1.1M
Earning Date
11-09-2026
11-12-2026
Dividend Yield
★ 5.66%
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$2.16
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$3.49
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$27.28
$6.50
52 Week High
$46.57
$39.49

Technical Indicators

Market Signals
Indicator
GSL
VOR
Relative Strength Index (RSI) 44.36 36.87
Support Level $37.00 $11.62
Resistance Level $45.07 $19.70
Average True Range (ATR) 0.93 1.23
MACD -0.28 -0.37
Stochastic Oscillator 18.37 23.02

Price Performance

Historical Comparison
GSL
VOR

About GSL Global Ship Lease Inc New

Global Ship Lease Inc is a containership owner, leasing ships to container shipping companies under industry-standard, fixed-rate time charters. Its fleet comprises mid-size Post-Panamax, Cypress, and smaller containerships, which tend to serve the faster-growing non-Mainlane and intra-regional trades, collectively representing the majority of the containerized trade volume globally. The company generates revenue from chartering its vessels to liner companies.

About VOR Vor Biopharma Inc.

Vor Biopharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of autoimmune diseases. Its program, telitacicept, is a potential first- and best-in-class dual BAFF/APRIL inhibitor designed to suppress the signaling pathways that drive the maturation, proliferation, and survival of harmful B cells, including self-reactive B cells, thereby reducing autoantibody production and preventing downstream tissue damage.

Share on Social Networks: